The SLCO1B1*15 haplotype associated with lower clinical outcome in Indonesian tuberculosis patients

Title	The SLCO1B1*15 haplotype associated with lower clinical outcome in Indonesian tuberculosis patients
Author Order	5 of 5
Accreditation	2
Abstract	Rifampin is one of first-line drugs for the treatment of tuberculosis. In Indonesia nearly alltuberculosis patients show lower rifampin plasma concentrations possibly due to genetics.Rifampin is a substrate of the organic anion-transporting polypeptide 1B1 (OATP 1B1)encoded by the solute carrier organic anion transporter family member 1B1 (SLCO1B1).This study aimed to identify haplotype polymorphisms of tuberculosis drug transporterswith an impact on clinical outcome in tuberculosis patients. Thirty-six patients from AbdulWahab Sjahranie General Hospital, Samarinda, East Kalimantan were involved in thestudy. Buffy coat from patient blood samples were tested for SLCO1B1 and SLCO1B3polymorphisms by RFLP and ARMS PCR, whereas the clinical outcome was examinedbased on the sputum conversion. The frequency of patients with SLCO1B1*15 haplotype was 63.9%. The SLCO1B1*15 haplotype was associated with susceptibility to failureof clinical outcome was markedly increased compared to the three other haplotypes. These results suggest that the SLCO1B1*15 haplotype is an important predisposing factor for lower clinical outcome. Our data indicate thatindividualized treatment should be considered for Indonesian tuberculosis patients basedon genetics characteristics of patients.
Publisher Name	Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
Publish Date	2018-03-26
Publish Year	2018
Doi	DOI: 10.19106/JMedSci005001201806
Citation	
Source	Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
Source Issue	Vol 50, No 1 (2018)
Source Page	
Url	https://jurnal.ugm.ac.id/bik/article/view/26048/pdf
Author	dr. MUSTOFA, S.Ked, M.Sc.